ASPMN Guidelines

American Society for Pain Management Nursing Guidelines on Monitoring for Opioid-Induced Advancing Sedation and Respiratory Depression: Revisions

Carla R. Jungquist, PhD, ANP-BC, FAAN *, Ann Quinlan-Colwell, PhD, RNC, AH, BC, FAAPM †, April Vallerand, PhD, RN, FAAN †, Heather L. Carlisle, PhD, DNP, RN-BC, FNP-BC, AGACNP-BC ‡, Maureen Cooney, DNP, FNP, RN-BC ‡, Susan J. Dempsey, MN, CNS, RN-BC, CCRN ¶, Danielle Dunwoody, PhD, RN, CNS §, Angelika Maly, RN †, Kathy Meloche, BSN, RN-BC **, Ashley Meyers, BSN, RN-BC, PCCN ‖, Jason Sawyer, RN-EC, BScN, MN, NP(BC) ††, Navdeep Singh, RN †, Denise Sullivan, RN, MSN, ANP-BC, ACHPN ¶¶, Chris Watson, MBA, BSN, RN-BC ‡‡, Rosemary C. Polomano, PhD, RN, FAAN ‡‡

* University at Buffalo, Buffalo, New York
† Private Practice Pain Management Consulting and Education, Wilmington, North Carolina
‡ Wayne State University, Detroit, Michigan
§ University of Arizona, Tucson, Arizona
¶ Westchester Medical Center, Valhalla, New York
¶ University of California, Los Angeles, Los Angeles, California
# University of Arizona, Tucson, Arizona
†† Harper University Hospital, Detroit, Michigan
‖ Sparrow Hospital, DeWitt, Michigan
¶¶ Sunnybrook Health Sciences Centre, Toronto, Canada
††† NYC Health + Hospitals/Jacobi, Bronx, New York
‡‡‡ East Alabama Medical Center, Opelika, Alabama
¶¶¶ University of Pennsylvania, Philadelphia, Pennsylvania

A B S T R A C T

Objectives: This report presents up-to-date evidence and expert consensus-based revisions to the ASPMN 2011 guidelines that inform interprofessional clinical decision-making for hospitalized adults receiving opioid analgesics.

Design: Systematic review of the literature.

Methods: A 14-member expert panel was charged with reviewing and grading the strength of scientific evidence published in peer reviewed journals and revising the ASPMN 2011 existing guidelines. Panel members formulated recommendations based on the strength of evidence and reached consensus through discussion, reappraisal of evidence, and voting by majority when necessary. The American Society of Anesthesiologists evidence categories for grading and classifying the strength of the evidence were used. Recommendations were subjected to a critical review by ASPMN members as well as external reviews.

Results: The 2011 guidelines were found to still be relevant to clinical practice, but new evidence substantiated refinement and more specific recommendations for electronic monitoring. The revised guidelines present risk factors divided into three categories: patient-specific, treatment-related, and environment of care. Specific recommendations for the use of electronic monitoring are delineated.

Conclusions: All hospitalized patients that are administered opioids for acute pain are at risk of opioid induced advancing sedation and respiratory depression, but some patients are at high risk and require extra vigilance to prevent adverse events. All patients must be assessed for level of risk. Adaptations to the plan of care and monitoring strategies should be driven by iterative re-assessments according to level of risk.

Address correspondence to Carla R. Jungquist, PhD, ANP-BC, FAAN, University at Buffalo, 3435 Main St., Wende 312, Buffalo, NY 14214.
E-mail address: Carlajun@buffalo.edu (C.R. Jungquist).

https://doi.org/10.1016/j.pmn.2019.06.007
1524-9042/© 2020 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.
Opioid-induced unintended advancing sedation (OIUAS) and opioid-induced respiratory depression (OIRD) can lead to serious consequences (e.g., hypoxic and anoxic brain injury with subsequent death) in hospitalized adult patients and have negative effects on health care systems (Fouladpour, Jesudoss, Bolden, Shaman, & Auckley, 2016; Overdyk et al., 2014; Weingarten, Chong, Schroeder, & Sprung, 2016). More than 50% of patients admitted to hospitals receive systemic and/or neuraxial opioid medications, and between 0.003% and 4.2% of those will experience an opioid-related adverse event (defined by naloxone administration or an opioid-related adverse drug event diagnosis code), including respiratory depression (Davis et al., 2017; Herzig, Rothberg, Cheung, Ngo, & Marcantonio, 2014; Kessler, Shah, Gruschkus, & Raju, 2013; Rosenfeld et al., 2016). Patients who experience an adverse opioid event are estimated to have 55% longer hospital stays, 47% higher costs of care, 36% increased risk of 30-day readmissions, with 3.4 times greater risk of inpatient mortality (Kessler et al., 2013). In cases of death or serious anoxic brain injury from an opioid-related event resulting in litigation, hospitals have paid financial penalties on average of $2.5 million (range $650,000–$7.7 million) (Fouladpour et al., 2016). Although opioid prescribing nationally has decreased since 2011, opioids remain a key component of multimodal perioperative analgesia (Jahr et al., 2017).

The continuing problem of opioid-related adverse events in hospitals has been a major focus by The Joint Commission (TJC), the Institute for Healthcare Improvement (IHI), and Centers for Medicaid and Medicare Services (CMS) (Centers for Medicare and Medicaid Services, 2014; Institute for Healthcare Improvement, 2012; The Joint Commission, 2017). In 2011 the American Society for Pain Management Nursing (ASPMN) published guidelines on monitoring for opioid-induced sedation and respiratory depression (Jarzyna et al., 2011). Despite these and other guidelines addressing how to assess, prevent, and manage OIUS and OIRD, these serious adverse events continue to occur. This report presents up-to-date evidence and expert consensus-based revisions to the ASPMN 2011 guidelines in response to requests from ASPMN members, other health care professionals, and health care organizations.

Methods

Expert Panel Composition

The ASPMN convened a 14-member expert panel (see author list) led by C.R.J. and R.C.P. The panel was charged with reviewing and grading the strength of scientific evidence published in peer-reviewed journals and revising the ASPMN 2011 existing guidelines. Conflicts of interest were evaluated for each panel member and disclosed according to ethical practice. Guideline panel members formulated recommendations based on the strength of evidence and reached consensus through discussion, reappraisal of evidence, and voting by majority when necessary. All recommendations were subjected to a critical review by ASPMN member representatives to enhance the integrity of the guideline development processes and reduce potential bias.

Scope and Target Users

These updated guidelines present the analysis of recent scientific literature and current recommendations to guide the implementation of standards of care for assessing and monitoring patients for opioid-induced unintended advancing sedation and respiratory depression. These guidelines inform interprofessional clinical decision making for hospitalized adults receiving opioid analgesics. The target users of these guidelines are members of the nursing staff, (e.g. clinical nurses, advanced practice registered nurses). These guidelines may also be useful for other members of the health care team and thus the term clinicians will be used. The focus of these guidelines is for hospitalized adult patients receiving systemic opioids (e.g., oral, intravenous [IV], transdermal, epidural) for the management of acute pain. Because there are up-to-date guidelines for the management of acute pain, the workgroup avoided duplication of pain management topics addressed by Chou et al. (2016). As such, recommendations may or may not pertain to patients receiving opioids solely for the treatment of chronic pain or those requiring end-of-life pain management.

Review of Evidence

The ASPMN guideline panel performed an extensive review of peer-reviewed journal publications over the past 10 years (time frame since last reviewed for 2011 manuscript). Panel members replicated search strategies (e.g., MeSH [Medical Subject Heading] terms and electronic databases) previously used in the development of the 2011 ASPMN guidelines (Jarzyna et al., 2011). Additionally, panel members expanded literature searches to encompass broader targets for topics such as electronic monitoring practices and devices, newer analgesics, and multimodal analgesic combinations to promote safe analgesia and reduce opioid-related adverse events. Literature searches were conducted through December 2017 and updated in October 2018.

Grading of Evidence and Recommendations

The panel once again applied the American Society of Anesthesiologists evidence categories for grading and classifying the strength of the evidence as adopted in the 2011 ASPMN guidelines (American Society of Anesthesiologists Task Force on Acute Pain Management, 2012; Jarzyna et al., 2011).

- Category A literature is considered strong and supportive.
- Category B literature is suggestive (in some situations such as assessing risk factors, where randomized controlled trials are not possible, this level of evidence is the strongest possible).
- Category C literature is considered equivocal.
- Category D reflects insufficient evidence.

Refer to the 2011 ASPMN guidelines for a complete description of this evidence grading system (Jarzyna et al., 2011) and Table 1 for a full explanation of levels of evidence. The panel then assigned a strength of the recommendation (strong or weak) and quality of evidence that the recommendation is based on (high, moderate, or poor) to each recommendation. The strength of the recommendation is derived from the evidence and consensus among panel members based on their expert opinions and knowledge of clinical practice. The strength rating balanced the risks versus benefits to patients as well as considered the demands of clinical care and burden to health care organizations. A strong rating represented...
the opinion that the benefits of the recommendation definitely outweigh the risks of any harm or burden of care. A weak rating indicated that a clinical recommendation may not be supported by strong evidence but may still be valuable to delivering safe patient care. The strength of the evidence is based on the type, number, size, and quality of the studies; strength of associations or effects on outcomes; and consistency of results among multiple studies. There was a scarcity of evidence to support development of recommendations. The lack of sufficient evidence led to the formulation of opinion-based evidence in the development of recommendations outlined in these guidelines.

Process for Guideline Revisions

The panel convened by teleconferencing in mid-2017 to discuss the guideline development process and formulate a plan to target revisions of the existing guidelines. During the conference call, panel members were asked to (1) identify current issues and problems with safe administration of opioids for acute pain; (2) examine the 2011 ASPMN existing guidelines for outdated or controversial information; and (3) evaluate the relevance of previous recommendations based on new research and evidence-based practice guidelines. Problems and shortcomings of the existing guidelines were discussed, and consensus was reached on areas of the guidelines requiring minor and major revisions. A new outline was created for the updated report, and panel members were assigned to subgroups reflecting division of work focused on individual patient, pharmacologic, and environment of care risks for OIUA and OIRD. Another subgroup formed to address monitoring practices such as nursing assessments of sedation and monitoring with electronic technology. Each group conducted extensive and more expansive literature searches than completed for the 2011 ASPMN guidelines, and retrieved, evaluated, and summarized relevant literature.

The panel met monthly by teleconferencing, with each subgroup reporting on their findings. Subgroup members updated sections of the existing 2011 ASPMN guidelines and formulated initial recommendations for guideline revisions. After all subgroups completed their work on the synthesis and grading of evidence, the panel drafted a list of new recommendations. Panel members modified the previous search and reporting categories to improve the translation of the guidelines to clinical practice. These changes included consolidating the search and reporting strategies to encompass patient-specific, treatment-related, and environment of care categories. Evidence from these categories was integrated and synthesized to formulate recommendations in each category. The patient-specific category included both risks associated with patient characteristics and clinical factors (e.g., comorbidities, type of surgery, length of surgery) that must be considered for safe patient care with opioid administration. The treatment-related category focused on research examining the use of pharmacologic agents and their association or, lack thereof, for advancing sedation and respiratory depression. Pharmacologic agents were analyzed independently and in combinations with other agents. Environments of care targeted studies on monitoring practices, plans of care, and nursing practice issues (e.g., staffing, resources). The panel organized recommendations based on these three distinct themes and graded the strength of scientific evidence.

The panel presented the newly drafted recommendations to interested members of ASPMN at the ASPMN annual meeting in September 2017. During the presentation, ASPMN members who attended provided feedback and discussed potential challenges or barriers to implementation of the revised guidelines. This feedback informed the final revisions to the guidelines outlined in this report.

Recommendations

Aligning Practice with Evidence and Standards

Recommendation 1

- The panel recommends that pain management strategies be individualized and aligned with peer-reviewed published evidence-based guidelines and The Joint Commission (TJC) current pain standards (strong recommendation, high-level evidence).
Rationale. Individualized perioperative (i.e., preoperative, intraoperative, and postoperative) pain management strategies that are tailored to patients, their procedures, and health conditions are necessary for the delivery of safe and effective pain management (Chou et al., 2016; The Joint Commission, 2017). Several evidence-based guidelines recommend the use of multimodal pain management that has opioid-sparing effects to decrease the incidence of opioid-related adverse events (American Society of Anesthesiologists Task Force on Acute Pain Management, 2012; National Comprehensive Cancer Network, 2018). Further support of opioid-sparing pain management is evident in the growing list of Enhanced Recovery After Surgery (ERAS) protocols (American Society of Enhanced Recovery, 2018; Tebala et al., 2016). Recent evidence has led TJC to update their standards for pain assessment and management requirements (The Joint Commission, 2017). This ASPMN panel endorses TJC standards to promote quality care and patient safety when opioids are part of patient-centered perioperative multimodal analgesia.

Implementation. Clinicians should participate in developing pain management plans with the interprofessional team for all hospitalized patients. These plans of care should incorporate multimodal therapy approaches that are aligned with current evidence-based guidelines and research. Fundamental to developing such plans, all clinicians need to be educated in pain assessment, including types of pain, risk factors for severe pain and analgesic side effects, functional goals, and how to communicate with patients about risk of treatment and preferences. Clinicians also need to be educated in the principles, rationale, and components of evidence-based multimodal analgesia, so they are aware of effective options available to reduce the use of opioids for managing pain.

Recommendation 2

- The panel recommends that clinicians recognize that all hospitalized patients receiving systemic (e.g., transdermal, IV, oral) or neuraxial opioids for acute pain management are at risk of opioid-induced unintended advancing sedation and opioid-induced respiratory depression. Some patients are at high risk for opioid-induced adverse events (Table 2) (strong recommendation, high level evidence).

Rationale. OIUAS and OIRD occur as the result of the action of opioids within the central nervous system and μ receptors suppressing the respiratory center in the brain. Opioids blunt the normal respiratory response to rising carbon dioxide and falling oxygen levels, which can lead to anoxic brain injury or death (Ladd et al., 2005; Lee et al., 2015; Sasaki, Meyer, & Eikermann, 2013). The incidence of adverse events from OIUAS and OIRD ranges between 0.6% and 4.2% (Cashman & Dolin, 2004; Herzog et al., 2014; Kessler et al., 2013). To address this continued problem, The Joint Commission, Institute for Healthcare Improvement, and Centers for Medicare and Medicaid Services recommend the (1) assessment of all patient and environmental risk factors, (2) implementation of systematic quality measures along with tracking opioid-related adverse events, and (3) education of all members of the health care team about risks with opioid administration (Centers for Medicare and Medicaid Services, 2014; Institute for Healthcare Improvement, 2012; The Joint Commission, 2017).

Table 2

Factors That Increase Risk for OIUAS and OIRD

<table>
<thead>
<tr>
<th>Patient-Specific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity hypoventilation syndrome (OHS)</td>
</tr>
<tr>
<td>• BMI &gt; 30 kg/m² and</td>
</tr>
<tr>
<td>• Arterial blood gas PaCO₂ &gt; 45 mm Hg (normal 35–45) or</td>
</tr>
<tr>
<td>• Serum HCO₃ &gt; 27 mmol/L (without other cause of metabolic alkalosis)</td>
</tr>
<tr>
<td>Known or suspected sleep-disordered breathing</td>
</tr>
<tr>
<td>• STOP-BANG total score &gt; 3 of 8</td>
</tr>
<tr>
<td>Diagnosis of obstructive or central sleep apnea</td>
</tr>
<tr>
<td>Comorbidities</td>
</tr>
<tr>
<td>• History of cardiac and/or pulmonary disease (previous or current smoker and/or need for supplemental oxygen)</td>
</tr>
<tr>
<td>• Impaired renal function (blood urea nitrogen &gt; 30 mg/dL)</td>
</tr>
<tr>
<td>• Impaired hepatic function (albumin level &lt; 30 g/L)</td>
</tr>
<tr>
<td>• Obesity—BMI &gt; 30</td>
</tr>
<tr>
<td>• Substantive functional limitations</td>
</tr>
<tr>
<td>American Society of Anesthesiologists (ASA) Physical Status Classification System &gt; 2</td>
</tr>
<tr>
<td>Substance use disorder (tobacco, alcohol, opioids, or other illicit substances)</td>
</tr>
<tr>
<td>History of or current (observed in the PACU) opioid-related sedation and/or respiratory event</td>
</tr>
<tr>
<td>Requirement for aggressive titration and dosing of opioids to manage pain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment-Related</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous opioid infusion in opioid-naive patients (e.g., IV PCA with basal rate)</td>
</tr>
<tr>
<td>Concomitant administration of sedating agents (e.g., benzodiazepines, antihistamines)</td>
</tr>
<tr>
<td>General anesthesia (especially if prolonged) as opposed to regional anesthesia</td>
</tr>
<tr>
<td>Surgical site (head, neck, chest, upper abdomen)</td>
</tr>
<tr>
<td>First 24 hours of initiating opioids (e.g., first 24 hours after surgery is a high-risk period for surgical patients)</td>
</tr>
<tr>
<td>Naloxone administration: Patients who are given naloxone for clinically significant opioid-induced respiratory depression are at risk for repeated episodes of respiratory depression</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Environment of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate hand-off communication of pertinent information related to risks for opioid-induced sedation and respiratory depression and monitoring requirements</td>
</tr>
<tr>
<td>Ineffective interprofessional communication of pertinent information related to risks for opioid-induced sedation and respiratory depression and monitoring requirements</td>
</tr>
<tr>
<td>Inadequate staffing that limits frequency of observations and safe monitoring practices</td>
</tr>
</tbody>
</table>

OIUAS — opioid-induced unintended advancing sedation; OIRD — opioid-induced respiratory depression; BMI — body mass index; PACU — postanesthesia care unit; IV — intravenous; PCA — patient-controlled analgesia.
Implementation. All patients must be assessed for risk of OIUAS and OIRD, and appropriate interventions should reflect level of risk. Clinicians need to be educated on assessing risk. Electronic health records should include evidenced-based assessment tools and methods to link appropriate safety measures that reflect the patient’s level of risk.

Recommendation 3

- The panel recommends that all patients who will receive opioids undergo a comprehensive assessment of level of individual risk before initiation of opioid therapy. Ongoing reassessment of risk that continues through the trajectory of clinical care is essential (strong recommendation, moderate level evidence).

Rationale. Several cohort studies have documented risk factors for opioid-related adverse events and the need for naloxone rescue (Khelemsky, Kothari, Campbell, & Farnad, 2015; Lee et al., 2015; Pawasauskas, Stevens, Youssef, & Kelley, 2014; Rosenfeld et al., 2016; Weingarten, Herasevich, et al., 2015; Weingarten, Warner, & Sprung, 2017). Please see Table 2 for a list of evidence-based patient risk factors.

Implementation. Screening patients for risk for OIUAS and OIRD should be an iterative process beginning before opioids are administered and continuing throughout a patient’s hospitalization. Acknowledging that it may not be feasible to prescreen all patients (whether or not they are being prescribed opioids) on admission to the hospital, it is necessary to screen all patients before initiating opioid therapy. A patient’s risk profile should always be documented in the electronic health record (EHR). EHR enhancements that link OIRD screening risk alerts to provider order entry systems may provide additional safeguards. Implementation of a risk factor checklist integrated into the EHR could also guide clinicians during a comprehensive assessment. Because assessment of risk should be an iterative process reflecting the response to care of a patient, it may be helpful to institute an EHR alert when a patient requires frequent doses of opioids, when a potential synergistic sedating medication is added, or when multiple formulations of opioids are used (e.g., long-acting oral opioid formulation in addition to short-acting or parenteral formulations). Implementation of this recommendation does require educating clinicians regarding the risk factors with relation to OIUAS and OIRD and how to appropriately intervene when an EHR alert is activated. Clinicians also need to be educated in how to assess patients on an ongoing basis throughout the trajectory of care and how to intervene when assessment yields concern.

Recommendation 4

- The panel recommends that ongoing individualized patient-centric plans of care be based on the patient’s level of risk, which may change over the course of hospitalization, and be developed, revised as needed, and communicated among all members of the patient care team (strong recommendation, moderate level evidence).

Rationale. Knowledge that poor communication increases the likelihood of adverse events has led organizations such as TJC, the World Health Organization, and IHI (Institute for Healthcare Improvement, 2018; The Joint Commission, 2017, 2018a; World Health Organization, 2017) to develop recommendations that focus on improving communication among clinicians. Assessing risk is only the first step in the process of ensuring safe pain management. Level of risk and recommendations for the appropriate monitoring strategies must be communicated to the patient, family, and entire health care team especially at handoff between levels of care and nursing shift changes (Bigani & Correia, 2018; Bittner-Fagan, Davis, & Savoy, 2017; Jewell & Committee On Hospital, 2016; Schirm, Banz, Swartz, & Richmond, 2018; Streeter & Harrington, 2017). Even though a patient may not be deemed high risk on preoperative assessment, a patient may still exhibit signs of OIUAS and OIRD while recovering in the postoperative care unit (PACU). Patients who exhibit OIRD in the PACU are 5–11 times more likely to have such an event on the general care unit (Weingarten et al., 2016). Effective communication among the health care team, especially in transitions of care, is known to improve patient safety (Thomas & MacDonald, 2016).

Implementation. The panel recommends multidisciplinary development and communication of a plan of care that includes pharmacists’ input into safe prescribing of medications. The plan of care should be developed and communicated at the time of risk assessment or reassessment and used diligently while the patient is receiving opioid analgesia. EHR enhancements should be used to alert all clinicians of risks for opioid-induced adverse events and to allow for structured handoff communication tools or criteria to communicate pertinent patient information related to monitoring plans of care and responses to pain management therapies (Eckstrand et al., 2009).

Recommendation 5

- The panel recommends that clinicians identify patients at high risk of opioid-induced unintended advancing sedation and opioid-induced respiratory depression by using evidence-based criteria, which includes the use of validated assessment scales/instruments (strong recommendation, high level evidence).

Rationale. Obstructive sleep apnea (Category B). Obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) are highly associated with OIUAS and OIRD (Fernandez-Bustamante et al., 2017; Gupta et al., 2018; Kaw et al., 2012; Nagappa et al., 2017; Shin et al., 2016; Weingarten, Herasevich, et al., 2015). Patients diagnosed with OSA or those who screen positive for OSA using the STOP-BANG questionnaire (Table 3) and experience an opioid-related respiratory arrest are more likely to experience a serious consequence such as anoxic brain injury and death (Fernandez-Bustamante et al., 2017; Fouladpour et al., 2016).

Obesity hypoventilation syndrome (Category B). Patients with obesity hypoventilation syndrome (OHS) are more susceptible to hyperventilation from opioids and more likely to (1) be admitted to the intensive care unit postoperatively, (2) require a tracheostomy, and (3) have increased hospital stays (Kaw et al., 2016). Diagnostic criteria for OHS are (1) body mass index (BMI) ≥30 kg/m², (2) hypoxemia (SpO₂ <90%) during sleep, and (3) hypercapnia during the day. The health care team can screen for OHS by assessing (1) BMI ≥30 kg/m², (2) daytime oxygen level (<95%), (3) PaCO₃ (via arterial blood gas) >45 mm Hg or serum HCO₃ >27 mmol/L (via admission chemistry profile) (Hart et al., 2014; Izrailtyan, Qiu, Overdyk, Erslen, & Gan, 2018; Manuel, Hart, & Stradling, 2015).

ASA classification (Category B). When more than one comorbid condition exists, the likelihood of developing postoperative complication such as OIUAS and OIRD is increased (Fernandez-Bustamante et al., 2017; Gupta et al., 2018; Khelemsky et al., 2015; Lee et al., 2015; Pawasauskas et al., 2014; Rosenfeld et al.,
substance use disorder, including opioid use disorder (Menendez, et al., 2017; Overdyk et al., 2014; Yung et al., 2017); presence of liver disease (Fernandez-Bustamante et al., 2017; Ramachandran et al., 2016; Zedler et al., 2018), renal impairment (Gupta et al., 2018; Nadpara et al., 2018; Ramachandran et al., 2017; Weingarten et al., 2016; Yung et al., 2015; Lee et al., 2015; Ramachandran, Pandit, Devine, Thompson, & Shanks, 2017; Rosenfeld et al., 2016; Weingarten et al., 2016).

Specific diseases (Category B). There is strong evidence supporting the use of the ASA classification score as a predictor of risk for OIUIAS and OIRD (Fernandez-Bustamante et al., 2017; Nadpara, Joyce, Carroll, Carpenter, Barnard, & Zedler, 2018; Pawsaskas et al., 2014; Ramachandran et al., 2017; Weingarten et al., 2016; Yung, Lee, Hsu, Furnish, & Atayee, 2017; Zedler, Saunders, Joyce, Vick, & Murrelle, 2018). Additionally, there is substantial evidence to indicate that patients with diabetes mellitus (Fernandez-Bustamante et al., 2017; Gupta et al., 2018; Nadpara et al., 2018; Ramachandran et al., 2017; Weingarten et al., 2016; Zedler et al., 2018), renal impairment (Dahan, Overdijk, Smith, Aarts, & Niesters, 2013; Fernandez-Bustamante et al., 2017; Khanna et al., 2019; Nadpara et al., 2018; Pawsaskas et al., 2014; Yung et al., 2017; Zedler et al., 2018), and heart failure (Khanna et al., 2019; Nadpara et al., 2018; Pawsaskas et al., 2014; Ramachandran et al., 2017; Yung et al., 2017; Zedler et al., 2018) could be at high risk for OIUIAS and OIRD.

Individual characteristics and other disease states (Category C). Although the evidence is weak, other individual risk factors potentially increase the likelihood for OIUAS and OIRD. These include age (Gupta et al., 2018; Khanna et al., 2019; Lee et al., 2015); liver disease (Fernandez-Bustamante et al., 2017; Ramachandran et al., 2017; Zedler et al., 2018); obesity (Fernandez-Bustamante et al., 2017; Overdijk et al., 2014; Yung et al., 2017); presence of substance use disorder, including opioid use disorder (Menendez, Ring, & Bateman, 2015; Nadpara et al., 2018; Zedler et al., 2018); being a smoker (Fernandez-Bustamante et al., 2017; Pawsaskas et al., 2014; Ramachandran et al., 2017); and presence of genetic variations in opioids pharmacokinetics (Madadi et al., 2013; Manini, Jacobs, Vlahov, & Hurd, 2013); and opioid tolerance (Khanna et al., 2019; Lee et al., 2015). In the past, opioid tolerance has been subject to varying definitions. According to the U.S. Food and Drug Administration (FDA), an opioid-tolerant patient is one who has been taking oral morphine 60 mg/day for a week or longer, or at least transdermal fentanyl 25 mcg/hour; oral oxycodone 30 mg/day; oral hydromorphone 8 mg/day; oral oxymorphone 25 mg/day; or an equianalgesic dose of any other opioid (U.S. Food and Drug Administration, 2018). It is critical for clinicians to understand that regular exposure to opioids does not guarantee protection from OIUAS and OIRD (Hayhurst & Durieux, 2016; Jolley, Bell, Rafferty, Moxham, & Strang, 2015).

Table 3

| Table 3 Assessment Strategies |

The STOP-BANG questionnaire is the most consistently applied validated instrument to screen for OSA (Chung et al., 2016).

- Although used widely in hospitals, there is sparse evidence on the sensitivity and specificity for detecting OIUAS and OIRD (Chung et al., 2016; Nagappa et al., 2017). In a study of postoperative patients, at least 18.3% of patients scoring <3 on the STOP-BANG developed moderate to severe sleep-disordered breathing after surgery (Chung et al., 2015). This finding in combination with results from other studies indicate that other factors are also predictive of patient risk for sleep-disordered breathing, calling for the need to expand screening procedures beyond the STOP-BANG questionnaire (Adams, Butts, & Spurlock, 2015).
- A total score of >3 out of 8 on the STOP-BANG questionnaire is considered a positive screen for OSA; a total score of ≥5 on the STOP-BANG instrument has been found to have 74% specificity and 56% sensitivity for the detection of OSA (Chung, Yang, & Liao, 2013; Nagappa et al., 2015).
- The total score of the STOP-BANG questionnaire should be used as opposed to just the individual items.

OSA – obstructive sleep apnea; OIUAS – opioid-induced unintended advancing sedation; OIRD – opioid-induced respiratory depression.

| Supplememental oxygen (category C). The routine use of 2-3 liters per minute of supplemental oxygen, during the first 24 hours after surgery, continues despite consistent supporting evidence (Al-Mobeirik & Abba, 2002; Allegranzi et al., 2016; American Society of Anesthesiologists Task Force on Neuromuscular Opioids et al., 2009; Gan et al., 2014; Myles & Kurz, 2017; Shapiro et al., 2005; Voepel-Lewis et al., 2013; Volk, Peters, & Sessler, 2017). Supplemental oxygen is recommended for patients experiencing intermittent or sustained hypoxia (<90%) after surgery (American Society of Anesthesiologists Task Force on Neuromuscular Opioids et al., 2009; de Raaff et al., 2017). Although the benefits of supplemental oxygen therapy in the postoperative setting is thought to outweigh the risks, higher concentrations (50%) of supplemental oxygen may be associated with more pronounced respiratory depression and negative health effects (Chu et al., 2018; Dahan, Douma, Olofson, & Niesters, 2016; Niesters, Mahajan, Aarts, & Dahan, 2013). Some authors contend that supplemental oxygen therapy may mask the detection of compromised respiratory status when using pulse oximetry as a method to assess blood oxygen saturation (Fu, Downs, Schweiger, Miguel, & Smith, 2004; Lam et al., 2017; Maddox, Williams, Oglesby, Butler, & Colclasure, 2006; Rozario, Sloper, & Sheridan, 2008; Shapiro et al., 2005; Sun et al., 2015; Whitney & Parkman, 2004). A recent study, however, disputes this notion that supplemental oxygen masks the detection of deteriorating respiratory status when monitoring with pulse oximetry (Taenzer, Perreard, MacKenzie, & McGrath, 2017).

Type of anesthesia (category B-1). Patients receiving general anesthesia tend to be at higher risk for OIUAS and OIRD compared with those given regional anesthesia (Khlemesky et al., 2015; Rosenfeld et al., 2016; Sultan, Gutierrez, & Carvalho, 2011).

Implementation. Comprehensive risk assessments for OIUAS and OIRD require use of reliable and valid instruments and policies to direct best practice. Electronic health record enhancement may be helpful to improve communication and provide timely safety alerts. Adding EHR alerts should be strategic to avoid alert fatigue. Organizational leaders should support continuing education for staff regarding roles and responsibilities to identify individual risk factors and appropriate monitoring and risk reduction interventions. It is
also necessary to assign responsibilities for nurses and other health care professionals in performing and communicating risk assessments across transitions of care. Assessing risk is only helpful if followed by applying appropriate interventions; therefore, practices should include actions and interventions to address and reduce risks. Organization leaders need to ensure that clinicians provide education for clinicians addressing individual risk factors, assessment of patients to identify risk factors, and appropriate risk reduction interventions to address risk factors, as well as the obligations/responsibilities of clinicians for safe care of patients at risk, including the transfer of patients to a higher level of care.

**Pharmacological Risk**

**Recommendation 6**

- The panel recommends that clinicians employ evidence-based pain management that incorporates opioid-sparing and multimodal analgesia therapies (strong recommendation, high level evidence)

**Rationale**

**Comparison of opioid analgesics (category A-1).** All full agonist opioid medications as well as partial agonists (e.g., tramadol, tapentadol, butorphanol, buprenorphine) can cause sedation and respiratory depression (Yung et al., 2017). Consequently, clinicians need to practice increased vigilance in assessing and monitoring all hospitalized patients receiving opioids for pain control to ensure effective and safe pain management (Chang, Bijur, Bacceliere, & Gallagher, 2009; Choi et al., 2008; Hutchison, 2006; Komatsu et al., 2007; Maestroni et al., 2007; Manolaraki et al., 2008; Sami Mebaza, Mestiri, Kaabi, & Ben Ammar, 2008; Tsutaoka, Ho, Fung, & Kearney, 2015; van der Schrier et al., 2017; Yassen et al., 2007; Zeng et al., 2015). The onset and severity of OIUAS and OIRD depend on many factors, including opioid formulation, dose, and mode of delivery; coadministration with other medications; and patient-centered factors related to drug absorption, metabolism, and elimination (Shenk et al., 2016; Takmaz et al., 2008; Weingarten, Hawkins, et al., 2015; Weingarten, Herasevich, et al., 2015; Zedler, et al., 2018). The selection of perioperative and acute pain analgesic regimens need to be evidence-based according to practice guidelines (Chou et al., 2016; Counsell, 2015; Hegmann et al., 2014; Schug et al., 2016). Multimodal analgesia can reduce opioid requirements, thus reducing risks for opioid-related adverse events, especially OIUAS and OIRD.

Multimodal analgesia is an important strategy for safe and effective pain management. It is important to consider the effect of coanalgesics and adjunct medications on sedation and respiratory depression when used in conjunction with opioids, and any potential risk must be evaluated. Classes of analgesics are presented next, and the category of evidence rating for the medications listed is the strength of the evidence that the medication either prevents or contributes to excessive sedation and respiratory depression when added to opioid medication.

**Acetaminophen (category A-1).** Although there is strong evidence that acetaminophen exerts opioid-sparing effects, most studies indicating reductions in opioid requirements with acetaminophen did not measure effects on respiratory depression or concluded that there were no significant differences in rates of respiratory depression (McNicoll et al., 2011; Moon, Lee, Lee, & Moon, 2011). A meta-analysis of intravenous acetaminophen in combination with opioids found reductions in 24-hour opioid requirements with open surgeries (Blank et al., 2018). A recent claims database analysis for perioperative use of acetaminophen with open colectomies revealed comparable opioid-related adverse event profiles between intravenous and oral acetaminophen use as an adjunct to opioid-based regimens (Wasserman et al., 2018).

**Nonsteroidal anti-inflammatory drugs (NSAIDs) (category A-1).** Clinical practice guidelines for ERAS protocols recommend the addition of NSAIDs as part of multimodal analgesia. (Carmichael et al., 2017; Tebala et al., 2016; Wick, Grant, & Wu, 2017). Authors of meta-analyses and individual studies conclude that nonselective NSAIDs are opioid sparing and reduce the incidence of opioid-induced sedation, but evidence on the effects on respiratory depression is lacking (Kumar, Kirksey, Duong, & Wu, 2017; Larson et al., 2014; Marret, Kurdi, Zufferey, & Bonnet, 2005; Wick et al., 2017). A comparison of intravenous ibuprofen 800 mg to acetaminophen 1,000 mg administered every 6 hours after bariatric surgery found that mean opioid requirements with IV patient-controlled analgesia (PCA) was less with ibuprofen (p = .055) (Erdogan Kayhan, Sanli, Ozug, Kirtek, & Yologlu, 2018).

Along with opioid-sparing effects, NSAIDs are associated with negative effects such as possible increased risk of bleeding and acute renal failure (Blouin & Rhaids, 2014; Shukla, Rai, Prasad, & Agarwal, 2017; Van Koughnett & Wexner, 2014; Warth et al., 2016). Patients should be carefully evaluated for potential risks from adverse events with NSAIDs.

**Anticoagulants (category A-1).** Anticoagulant medications, including gabapentin and pregabalin, are commonly recommended as part of ERAS protocols and clinical practice guidelines (Carmichael et al., 2017; Chou et al., 2016). There is substantive evidence that gabapentinoids (pregabalin up to 300 mg preoperatively or 75 mg bid for 5 days and or gabapentin 600 mg bid) are opioid-sparing and are not associated with serious opioid-induced adverse events (Balaban, Yagar, Ozgok, Koc, & Gullapoglu, 2012; Gianesello, Pavoni, Barboni, Galeotti, & Nella, 2012; Gurunathan, Rapchuk, King, Barnett, & Fraser, 2016; Kim et al., 2011). Recent systematic reviews, however, warn of possible increased sedation from gabapentin and pregabalin (Cavalcante, Sprung, Schroeder, & Weingarten, 2017; Fabritius, Geisler, et al., 2017; Fabritius, Strom, et al., 2017; Fabritius, Weterslev, Mathiesen, & Dahl, 2017; Savelloni et al., 2017; Yung et al., 2017).

**Antidepressants (category C-2).** Existing research primarily focuses on the use of antidepressants in the treatment of chronic (persistent) pain. There is weak evidence of increased somnolence when nortriptyline or mirtazapine are administered in combination with opioids medications (Gilron, Tu, Holden, Jackson, & DuMerton-Shell, 2015; Mehta & Roth, 2015; Rowbotham, 2015).

**Clonidine (category B-2).** Clonidine is a centrally acting agonist used to treat central pain syndromes; however, evidence suggests a useful role as an opioid-sparing medication with anesthesia and analgesia (Blaudszun, Lysakowski, Elia, & Tramer, 2012; Tripathi, Shah, Dubey, Doshi, & Raval, 2011). Studies document increased sedation when clonidine is added to opioid-based regimens (Huang et al., 2007; McCartney, Duggan, & Apatu, 2007; Vukovic, Ramakrishnan, & Milan, 2012) but no appreciable effects of clonidine in causing respiratory depression.

**Ketamine (category A-1).** Ketamine, an anesthetic agent that induces sedation and memory loss, is used in subanesthetic doses as an analgesic for acute pain. There is sufficient evidence to document the role of low-dose ketamine in reducing opioid requirements without increasing risk of respiratory depression (Laskowski, Stirling, McKay, & Lim, 2011; Mathews, Churchhouse, Housden, & Dunning, 2012; Parikh, Maliwad, & Shah, 2011; Rakhman et al., 2011; Sen et al, 2009). Although low-dose ketamine may be beneficial as part of multimodal pain management, even at low doses patients can experience adverse effects such as delirium, agitation, dysphoria, hallucinations, vivid dreams, and sedation (Schwenk et al., 2016).
**Dexmedetomidine** (category A-1). Dexmedetomidine, indicated for purposeful sedation of mechanically ventilated patients, also has opioid-sparing effects and decreases pain intensity without posing significant risks for respiratory depression in postoperative populations (Bharti, Sardana, & Bala, 2015; Blaudszuun et al., 2012; Garg et al., 2016; Song, Shim, Song, Kim, & Kwak, 2016; Technivane, Dusitkasem, & Auwattanavanit, 2012).

**Benzodiazepines** (category B-1). Benzodiazepines are commonly used during anesthesia because they promote relaxation and amnesia. Lately, attention to the combination of opioids with benzodiazepines has raised awareness of serious interactions in outpatients, leading to opioid overdose and even deaths (Food and Drug Administration, 2016; Gressler, Martin, Hudson, & Painter, 2017). Coadministration of benzodiazepines with opioid analge-sics in the in-patient setting also carries a significant risk for respiratory depression, secondary to its potential to produce sedation (Gordon & Pellino, 2003; Griffiths et al., 2012; Izraliytn et al., 2018; Kim, McCarthy, Mark Courtney, Lank, & Lambert, 2017; Lee et al., 2015; Lyons et al., 2017; Overdyk et al., 2016; Ramachandran et al., 2017; Silva et al., 2015; Zedler et al., 2018). This has prompted the Food and Drug Administration to issue warnings regarding coprescribing of opioids and benzodiazepines (U.S. Food and Drug Administration, 2016).

**Antihistamines** (category C). It was once thought that antihis-tamine medications such as diphenhydramine were helpful in treating pain and reducing postoperative nausea and vomiting (Lin et al., 2005; Tu et al., 2006). More recent evidence has led clinicians to be concerned about the synergistic effects resulting in OIUsA and OIRD when antihistamines are added to opioid regimens (Becker, 2012; Siddik-Sayyid et al., 2010). Unfortunately, there is not strong evidence to substantiate this assumption. A recent study, however, documented the lack of opioid-sparing effects of diphenhydramine in postoperative pain in doses up to 50 mg but failed to address effects on sedation or respiratory depression (De Oliveira, Bialek, Marcus, & McCarthy, 2016). Ondanestron, although effective for postoperative nausea and vomiting, does not appear to be associated with respiratory depression (Moslemi, Rasooli, Baybordi, & Golzari, 2015; Moustafa, Baaror, & Abdelazim, 2016; Zhou, Huang, Lu, Zhang, & Zhang, 2015).

**Implementation.** In order for clinicians to participate in clinical decision making around the administration of multimodal analge-sia, they must be educated about effectiveness, synergistic adverse effects, and contraindications to its use. Using EHR alerts at time of entering prescriptions may act as a reminder. Other sources for supporting the patient's opioid history can be obtained via the American Society of PeriAnesthesia Nurses in identifying safe staffing levels. The panel recognizes the work of the American Society of PeriAnesthesia Nurses in identifying safe staffing ratios in the PACU and making this a top priority for national research agendas (Mamaril, Ross, Poole, Brady, & Clifford, 2009).

**Purposeful rounding.** (category C). There are no definitive data indicating that intentional hourly rounding improves detection of opioid-induced adverse events. Moderate strength of evidence exists supporting improvements in patients' perception of nursing responsiveness and reductions in patient falls and call light use (Mitchell, Lavenberg, Trotta, & Umscheid, 2014). There is weak evidence (one quality improvement project) supporting hourly rounding to improve pain management. Hourly rounding to address pain issues in the context of a quality improvement project led to an increase in patient satisfaction with pain outcomes (Daniels, 2016). Extending the focus to purposeful rounding for monitoring patients receiving opioids holds promise for improving early detection of opioid-related adverse events.

**Environment of Care**

**Recommendation 7**

- The panel recommends that hospital policies and procedures reflect evidence-based and nationally published standards and ensure (1) effective communication among all members of the patient care team, (2) adequate and safe staffing ratios, and (3) purposeful hourly rounding by nursing staff (strong recommendation, weak to high levels of evidence)

**Rationale**

**Communication** (category C). Evidence-based and standardized methods of communication at transitions of care and shift-to-shift handoffs can decrease the risk of adverse events in the peri operative setting (Institute for Healthcare Improvement, 2018; Riesenberg, Leitzsch, & Cunningham, 2010; Robinson, 2016; The Joint Commission, 2018a). Clinicians value structured communication handoff tools to improve patient safety (Lane-Fall et al., 2014). There is strong evidence to indicate that effective collaboration and communication among health care professionals in the perioperative setting improve patient outcomes and support a culture of patient safety (Institute for Healthcare Improvement, 2018; Magill et al., 2017). Despite recommendations that institutions develop standardized communication procedures for health care teams, a limited number of studies have determined criteria and mechanisms of communication that ensure safe and effective pain management.

**Staffing and practice environment** (category C). The previous 2011 ASPMN consensus report on monitoring for OIUsA and OIRD detailed numerous studies that address staffing practices for optimal patient care. Clinicians should consult this report for an analysis of research pertaining to nurse staffing and its relationship to achieving safe patient care and outcomes. Research is still lacking to determine specific staffing guidelines for sedation and respira tory monitoring with opioid analgesics. However, the ASPMN expert panel continues to endorse compliance with state mandates, standards promulgated by professional organizations, and institution-specific staffing procedures and acuity measures to determine safe staffing levels. The panel recognizes the work of the American Society of PeriAnesthesia Nurses in identifying safe staffing ratios in the PACU and making this a top priority for national research agendas (Mamaril, Ross, Poole, Brady, & Clifford, 2009).

**Environment of Care**

**Recommendation 7**

- The panel recommends that hospital policies and procedures reflect evidence-based and nationally published standards and ensure (1) effective communication among all members of the patient care team, (2) adequate and safe staffing ratios, and (3) purposeful hourly rounding by nursing staff (strong recommendation, weak to high levels of evidence)
and clinical decision-making criteria in determining the appropriate level of care to ensure optimal patient safety.

**Monitoring**

**Recommendation 8**

- The panel recommends that the nature, timing, frequency, and intensity of monitoring practices be based on ongoing nursing assessment and reassessment of patients’ risks and response to pain therapies. Adaptations to the plan of care are driven by iterative assessments (strong recommendation, moderate level of evidence).

**Rationale.** Identifying risk factors for OIUAS and OIRD is an iterative process that informs the need to increase or decrease vigilance with monitoring practices. Clinical staff have the responsibility to obtain knowledge of risk factors and apply critical thinking skills in the adaptation of patient assessment data into level of monitoring vigilance. As recommended by the Chou et al. (2016) guidelines, endorsed by several professional organizations, for the management of postoperative pain, clinical staff should perform a thorough history and physical examination to develop an individually tailored pain management plan of care. This comprehensive evaluation should also include assessing the patient’s risk of opioid adverse events, including respiratory depression. See Table 2 for list of risk factors.

**Implementation.** An individualized pain management plan should include recommendations for assessment and monitoring procedures. When developing the initial plan for monitoring procedures, three main issues must be considered: (1) patient risk factors, (2) formulation of opioid, and (3) presence of respiratory interventions such as oxygen therapy, artificial ventilation, or positive airway pressure therapy. The assessment process is iterative and should be ongoing and adjusted according to the patient’s responses to clinical care. The organization leaders need to provide education for clinicians regarding the potential safety risks of opioids, the importance of consistent assessment and monitoring, the organization’s requirements for each, and how to intervene when patient risk increases during hospitalization including potential transfer to a higher level of care.

**Recommendation 9**

- The panel recommends evidence-based systematic nursing assessments for opioid-induced unintended advancing sedation and respiratory depression inclusive of (1) level of sedation, (2) respiratory rate and quality, and (3) oxygen saturation before initiation of opioid therapy, before administering an opioid dose, and at peak effect of opioid and/or other sedating medication coadministered within the therapeutic window of an opioid. Systematic nursing assessments should not be replaced with continuous electronic monitoring (strong recommendation, moderate level evidence).

**Rationale.** There is strong evidence (category B-1) that the incidence of opioid-related adverse events such as OIRD is highest in the first postoperative 24 hours (Epstein, Dexter, Lopez, & Ehrenfeld, 2014; Lee et al., 2015; Rosenfeld et al., 2016; Weingarten, Herscovitch, et al., 2015). There is also moderate quality evidence (category B-2) that increasing vigilance from every 4 hours to using continuous monitoring or assessments to every ≤2.5 hours during the first 24 hours will decrease the use of naloxone and rapid response team calls (Adams, Butas, & Spurlock, 2015; Jungquist et al., 2016; Lam et al., 2017; Sites, Surprise, McNiel, Northrop, & De Ruyter, 2017).

Nurses increasingly are expected to assume an integral role in improving patient safety (Institute for Safe Medication Practice [ISMP], 2013; The Joint Commission, 2017; World Health Organization, 2017). Although there are few rigorous studies to base specific monitoring practices, there are published guidelines that provide strong recommendations based in expert opinion (American Society of Anesthesiologists Task Force on Acute Pain, 2012; American Society of Anesthesiologists Task Force on Neuraxial Opioids et al., 2009; Chou et al., 2016; Chung et al., 2016; Jarzyna et al., 2011; Schug et al., 2016). There is consistent agreement among published guidelines that the frequency, intensity, and duration of monitoring should be based on the type of opioid therapy, patient risk factors, and response to treatment, and that current nursing assessments every 4 hours may not be adequate for early detection of opioid-induced adverse events. In one study instituting increased nursing assessments (every 1 hour for 12 hours, then every 2 hours for 12 hours) and the Pasero Opioid-Induced Sedation Scale, the facility documented no adverse opioid-related events after the policy was effectively instituted (Smith, Farragony, & Matthews, 2014).

Debates exist regarding whether patients on opioids should be monitored using continuous electronic monitoring devices for their entire hospital stay, as evidenced by variations in hospital practices (Jungquist, Willens, Dunwoody, Klingman, & Polomano, 2014). Although mentioned in a 2012 TJC alert, TJC has not recommended continuous electronic monitoring of all patients on opioids. Developing highest level and rigorous evidence to substantiate continuous monitoring of all patients would require longitudinal randomized controlled trials with large sample sizes that are representative of diverse hospitalized populations limiting the feasibility of such studies. Thus clinicians must depend on available evidence and the ethical tenant of “do no harm.” Patients are hospitalized because they are not safe and stable to be cared for at home. Hospital administrators and clinicians are responsible for the safety of the patient and thus must provide, at minimum, intermittent pulse oximetry, especially at peak effect of opioid pain medications. Because of the accumulation, summation, and clearance factors of anesthetic and pain medications, along with the increased collapsibility of the airway during sedation and sleep during the first 24 hours after surgery, it is not always clear when peak effect is occurring. Nurses on the general care units cannot observe patients at all times; thus instituting continuous electronic monitoring will aid nurses in the detection of respiratory issues and improve patient safety. To date, none of the published guidelines advocate for continuous electronic monitoring of respiratory status in all patients receiving opioid medications, despite increased awareness from organizations such as the Anesthesia Patient Safety Foundation and the Association for Advancement of Medical Instrumentation (Weingarten, 2011; Williams, 2015). Evidence-based published guidelines are recommending continuous electronic monitoring of those at higher risk. Continuous electronic monitoring of all patients can lead to the problem of alarm fatigue, added work demands, and activity restrictions when patients are tethered to their bed.

Alarm fatigue can be associated with patient harm. According to TJC, there were 98 alarm fatigue-related sentinel events (death or serious permanent patient harm) reported between 2009 and 2012, with 80 of the 98 events resulting in patient death. Additionally, The U.S. Food and Drug Administration reported 500 alarm-related deaths over a 5-year period (The Joint Commission, 2013). Although tested measures to combat alarm fatigue are evolving, the best ways to combat this concerning problem are yet to be determined.
Table 4
Assessment Strategies

<table>
<thead>
<tr>
<th>Sedation Scales</th>
</tr>
</thead>
</table>
| In a survey of ASPMN members (N = 102), respondents identified the most common sedation scales used at their institution. These included the Pasero Opioid-Induced Sedation Scale (POSS), Richmond Agitation-Sedation Scale (RASS), Ramsay Sedation Scale (RSS), and Sedation-Agitation Scale (SAS). Other, less common, sedation scales were the Aldrete Scale, Riker Scale, Motor Activity Assessment Scale, Glasgow Coma Scale, University of Michigan Scale, and other individually developed institutional scales (Jungquist, Willens, et al., 2014).
| Seventy-six percent of ASPMN members endorsed utilizing a sedation scale with opioid therapy for pain, and 66% felt that the use of scales was important to preventing and detecting adverse events (Jungquist, Willens, et al., 2014).
| The RASS is often used in intensive care units (ICUs) for intentional sedation (Bush et al., 2014; Kobelt, Burke, & Renker, 2014) but is also used on general care units when evaluating levels of sedation with limited data to document its utility with opioid-induced sedation (Nisbet & Mooney-Cotter, 2009).
| The POSS provides guidance for clinical decision making with interventions or actions that can be taken by clinicians in response to concerning levels of sedation. Reliability and validity have been established for the POSS for use on general care units in monitoring patients receiving opioid analgesics (Bartoszek et al., 2017; Cooper, Stannard, & Noble, 2015; Davis et al., 2017; Kobelt et al., 2014; Nisbet & Mooney-Cotter, 2009; Quinlan-Collwell, Thear, Miller-Baldwin, & Smith, 2017; Saveloni et al., 2017).
| Validated and standardized sedation scales or measures should be incorporated in routine monitoring of patients receiving opioids to guide critical thinking skills and informed decisions about managing pain, sedation, and patient safety.

ASPMN — American Society for Pain Management Nursing.

Studies thus far have not been convincing in identifying the benefits of continuous monitoring in yielding reduced rates for serious opioid adverse events. Research is needed to compare prevention and detection rates of OIUAS and OIRD between intermittent and continuous monitoring. Until such evidence exists, this panel recommends nursing assessments (respiratory rate and quality, level of sedation, oxygen saturation) before initiation of opioid therapy, before administering a dose, and at peak effect. In addition to nursing assessment, continuous electronic monitoring between nursing assessments may be warranted in high-risk patients. After the first 24 hours, the timing of assessments and duration of electronic monitoring should be adjusted according to patient status and responses to therapy.

**Sedation scales (category B-3).** Growing evidence indicates the value of using reliable and valid sedation scales to quantify and describe opioid-induced sedation (Dunwoody & Jungquist, 2018). Sedation or altered level of consciousness is a common effect of opioids, and unintended advancing sedation is a serious adverse event that often precedes opioid-induced respiratory depression (Ghelardini, Di Cesare Mannelli, & Bianchi, 2015; ISMP, 2013; Macintyre, Loadman, & Scott, 2011; Motov, Rosenbaum, Vilke, & Nakajima, 2016; Oosten et al., 2011; Smith et al., 2014; Yamamotova, Fricova, Rokytka, & Slamberova, 2016). Clinicians continue to emphasize the importance of routine assessments of sedation levels as part of monitoring practices for opioid-related adverse events (Dalton et al., 2001; Gordon, Pellino, Higgins, Pasero, & Murphy-Ende, 2008; Hayes & Gordon, 2015; Jarzyna et al., 2011; Pasero, 2009). See Table 4 for additional information regarding sedation assessment.

**Respiratory rate and quality (category B-2).** The ability to assess respiratory status with opioid therapy requires attention to breathing patterns (ISMP, 2013).

Clinicians should observe breathing during sleep, then wake the patient to assess level of sedation. Waking the patient is critical to providing safe patient care. See Table 5 for additional information regarding respiratory assessment.

**Intermittent pulse oximetry (category B-2).** The oldest and most often used device to monitor for OIRD is pulse oximetry. The 2014 ASPMN membership survey (N = 102) found that 28% of nurses from unique hospitals endorsed using intermittent pulse oximetry to assess for OIRD (Jungquist, Willens, et al., 2014). Although expert panel members agree that the use of intermittent pulse oximetry has increased over time, many hospitals still face limited availability of pulse oximetry devices to safely monitor the high volume of patients receiving opioid analgesics (Willens, Jungquist, Cohen, & Polomano, 2013). See Table 6 for additional information regarding pulse oximetry.

**Heart rate (no evidence rating).** Cardiac electronic monitoring can be beneficial along with respiratory monitoring to detect changes in heart rate indicative of ensuing or actual respiratory

Table 5
Assessment Strategies

<table>
<thead>
<tr>
<th>Respiratory Rate, Depth, and Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Because sleep states pose risks for pharyngeal collapsibility that may be increased with sedating agents and lack of voluntary control of breathing, it is important for clinicians to be extra vigilant with monitoring practices when patients are sleeping to ensure patient safety (Ehsan, Mahmoud, Shott, Amin, &amp; Ishman, 2016; Jungquist, Smith, Nicely, &amp; Polomano, 2017; Kulkas et al., 2010; Dudette et al., 2018).</td>
</tr>
<tr>
<td>The clinician should assess the respiratory status by observing the respiratory rate and depth and quality of respirations in the awake patient at rest and the sleeping patient before being aroused for 1 full minute.</td>
</tr>
<tr>
<td>Normal awake respiratory rate for adults younger than 65 years ranges between 12-18 breaths per minute (BPM). Normal respiratory rate during sleep should remain between 12-20 BPM in patients younger than 60 years, 12-28 BPM between 65-80 years, and 10-30 BPM in those older than 80 years (Plenady, Dwyer, &amp; Applegarth, 2017; Rodriguez-Molinero, Narvaiza, Ruiz, &amp; Galvez-Barron, 2013).</td>
</tr>
<tr>
<td>A patient experiencing OIUAS and OIRD may exhibit a respiratory rate &lt;12 breaths per minutes initially, but then as the body compensates, rates may increase to greater than 18 breaths per minute (Al-Khabori et al., 2014; Drummond, Dhonneur, Kirov, &amp; Duvaldestin, 2013).</td>
</tr>
<tr>
<td>Quality of breathing involves assessment of depth and rhythm. Tidal volume, represented by the depth of breath, decreases during sleep, at which time breathing may appear shallower (Rodriguez-Molinero, Narvaiza, Ruiz, &amp; Galvez-Barron, 2013).</td>
</tr>
<tr>
<td>The quality of rhythm of breathing during wakefulness should remain steady, but normal breathing rhythms during REM sleep may be irregular (Krieger, Maglasiu, Sforza, &amp; Kurtz, 1990). In the presence of opioids and other sedating medications, tidal volume or depth of breath may be shallow, and rhythm may be irregular representing pharyngeal collapsibility/apneic events (Al-Khabori et al., 2014; Drummond et al., 2013).</td>
</tr>
<tr>
<td>Clinicians should use their auditory senses to listen for snoring, which is a sign of varying degrees of pharyngeal collapse (Alakuijala &amp; Salmi, 2016; Hong et al., 2017; Koo et al., 2017).</td>
</tr>
<tr>
<td>Much like patients with OSA, patients experiencing OIUAS and OIRD could exhibit noisy breathing and a distinct pattern with pause in breaths for more than 10 seconds, then a louder snore as they arouse to open their airway (Wu et al., 2016).</td>
</tr>
</tbody>
</table>
Pulse oximetry is a reliable and valid measure of the percentage of red blood cells that are saturated with oxygen and can be accomplished using a probe that rests on the end of a finger (Al-Khabori et al., 2014). The finger sensor should be gently applied to the finger and occur with the patient at rest and/or during sleep. The most accurate reading will be the one that stabilizes and is present for the majority of the 60 seconds (Stausholm, Rosenberg-Adamsen, Edvardsen, Kehlet, & Rosenberg, 1997). Factors that can interfere with accuracy of pulse oximetry are dark-colored nail polish, vasconstriction (e.g., Raynaud’s or sickle cell diseases), hypotension, and hypothermia (Desalu, Diakporomere, Salami, & Abiola, 2013; Hakverdioglu Yont, Akin Korhan, & Dizer, 2014; Stausholm et al., 1997). Normal awake oxygen saturation in adults is 95% but can range 91% to 100% in adults older than 65 years. The limit of low normal in elderly patients is 91% (Rodriguez-Molina et al., 2013). During sleep, oxygen saturation should remain >92%.

In the absence of supplemental oxygen, signs of respiratory compromise are (1) sustained periods of intermittent oxygen desaturation lasting at least 10 seconds <90% during sleep, (2) average oxygen saturation <92%, (3) respiratory rate <10 BPM, or (4) 3% drop in pulse oximetry lasting more than 15 minutes after a parenteral opioid is administered (Chung et al., 2012). Recognizing slow patient deterioration and the summation effective of multiple doses of opioids requires comparing current pulse oximetry data with preopioid data as well as changes over time.

Patients who experience repeated oxygen desaturations dipping to 83% during sedation or sleep have impaired arousal thresholds and may be at higher risk of respiratory arrest when given sedating medications (Edwards et al., 2014). Supplemental oxygen therapy can mask hypoventilation (Fu et al., 2004; Lam et al., 2017; Maddox et al., 2006; Rozario et al., 2008; Sun et al., 2015). For an accurate assessment of actual oxygen saturation, supplemental oxygen should be removed for at least 5 minutes before assessment of oxygen saturation.

Documentation of oxygen saturation should include whether the assessment occurred with or without supplemental oxygen.

Continuous pulse oximetry can be discontinued after 24 hours if parenteral or neuraxial opioids are stopped, as long as the patient does not demonstrate continued high-risk factors and does not have signs of trending or actual OIRD.

The alarm threshold for pulse oximetry is typically <90%. There is some evidence that an alarm threshold of 88% decreases the rate of false alarms without increasing sentinel OIUAS and OIRD events (Taenzer, Pyke, Herrick, Dodd, & McGrath, 2014).

Supplemental oxygen therapy can mask hypoventilation when integrated respiratory and cardiac monitoring systems provide surveillance of changes in cardiac status secondary to pain and respiratory depression (Helfand, Christensen, & Anderson, 2011). The need for cardiac monitoring with opioids should be determined based on a patient’s health status, criteria for such monitoring, and environments of care where telemetry and cardiac monitors are available.

**Implementation.** The recommended procedure for intermittently measuring oxygen saturation using pulse oximetry is similar to assessment of respiratory quality and depth. Clinicians should be especially vigilant, increasing assessment for respiratory compromise when the patient’s respiratory status is the most vulnerable.

**Recommendation 10**

- The panel recommends that all patients deemed to be at risk for opioid-induced unintended advancing sedation and opioid-induced respiratory depression be evaluated for continuous electronic monitoring (Table 2); and that the type of electronic monitoring be appropriate to the condition of the patient, presence of supplemental oxygen or positive airway pressure therapy, patient’s response to care, patient comfort and adherence to monitoring device, and detection capability of the technology (strong recommendation, weak level evidence).

**Rationale.** There are four types of continuous electronic monitoring devices available for clinical use on general medical/surgical units: (1) pulse oximetry/oxygen saturation, (2) acoustic respiratory rate monitor, (3) capnography/end tidal carbon dioxide, and (4) minute ventilation monitor. Making decisions as to the best type of electronic monitoring device requires a full understanding of breathing pattern changes that occur after an opioid dose is delivered. Once a parenteral dose of opioid is administered, the first change is a decrease in respiratory rate, followed by a decrease in tidal volume. The resulting hypoventilation can cause a rise in carbon dioxide and subsequent decrease in oxygen saturation (Leino, Mildh, Lertola, Seppala, & Kirvela, 1999). Pulse oximetry monitoring, although common, is, at some hospitals, being replaced or augmented with capnography and minute ventilation monitoring practices based on expanding science in the etiology of OIRD and the availability of new capnography and minute ventilation devices.

**Pulse oximetry (category B-1).** There is sufficient research and expert consensus recommending the use of pulse oximetry to detect OIRD with opioid-based therapies after surgery (American Society of Anesthesiologists Task Force on Neuraxial Opioids et al., 2009; Chung et al., 2012; Lam et al., 2017; Miner et al., 2013; Pedersen et al., 2014; Sivilotti, Messenger, van Vlymen, Dungey, & Murray, 2010; Voepel-Lewis et al., 2013). Continuous pulse oximetry monitoring is preferred for all patients at high-risk, recognizing that all patients are at high risk in the first 24 hours after initiating parenteral opioid therapy. See Table 6 for additional information regarding pulse oximetry. The use of pulse oximetry devices may be an ineffective method of respiratory assessment in patients who require supplemental oxygen or have a history of moderate to severe lung disease or obesity hypoventilation syndrome. Patients with moderate to severe lung disease and or OHS are more likely to retain carbon dioxide. In those patients, the use of capnography assessment may be indicated.

Examining trends in monitoring data is critical to early detection of compromised respiratory status and provides opportunities for early interventions such as decreasing doses of opioids, discontinuing opioids, and/or maximizing analgesia with opioid-sparing pain therapies. When interpreting pulse oximetry readings, it is important for nurses to use trend monitoring analysis of patient data to interpret current pulse oximetry values relative to baseline or preopioid values. For example, if a patient’s baseline/preopioid oxygen saturation is 100% and readings are progressively declining with the administration of opioids, the patient is showing signs of changes in respiratory status.

**Capnography (category B-1).** Sufficient evidence exists validating capnography as an effective method to monitor for respiratory compromise (Heines, Strauch, Roekaerts, Winkens, & Bergmans, 2013; Kim, Choi, Bang, & Lee, 2016). Capnography is
more effective in detecting respiratory depression events in contrast to intermittent every-4-hour pulse oximetry assessments (Hutchison, 2006). Other clinical studies have compared capnography with pulse oximetry and found capnography superior in detecting OIRD (Lam et al., 2017; Oswald, Zeuske, & Pfeffer, 2016; Sivilotti et al., 2010). See Table 7 for additional information on capnography.

Minute ventilation (category B-1). Minute ventilation is measured using a respiratory volume monitor. Clinical studies indicate that monitoring minute ventilation is effective, comfortable for the patient, and in some cases more effective in detecting OIRD than measuring respiratory rate, oxygen saturation, or end tidal CO2 (Ebert, Middleton, & Makhiya, 2017; Galvagno, Duke, Eversole, & George, 2016; Holley et al., 2016; Mehta, Cattano, Brayanov, & George, 2017; Vocopoulos, Theos, Tillmann Hein, & George, 2017; Vocopoulos et al., 2014). See Table 8 for additional information on minute ventilation.

Acoustic respiratory rate (category C-2). The first change in breathing patterns with OIUA and OIRD is a decrease in respiratory rate. This device measures rate of breathing through a transducer attached to the patient’s neck. Other clinical studies document the reliability and validity of the device, there is weak evidence that acoustic respiratory rate monitoring by itself reduces adverse events (Yang et al., 2017). There is evidence that in studies of postoperative respiratory depression, episodes of oxygen desaturation occurred that were not detected by changes in respiratory rate (Kawanishi, Inoue, & Kawaguchi, 2017; Ouchi, Fujiiwara, & Sugiyama, 2017). Authors recommended pairing the acoustic respiratory rate monitor with pulse oximetry for more sensitive detection of OIRD (McGrath, Pyke, & Taenzer, 2017).

Implementation. The expert panel recommends a paradigm shift from only monitoring to a criterion threshold (e.g., a set value for determining a potential serious adverse event) to including a combination of threshold and trend monitoring. Trend monitoring refers to examining patterns of change in patient monitoring data over time (e.g., a few hours, over a shift or 24 hours) to evaluate if monitoring outcomes are worsening, improving or remaining stable. Trend monitoring considers multiple variables such as respiratory rate, level of sedation, and ventilator parameters derived from electronic devices such as pulse oximetry, end tidal CO2, and minute ventilation. This type of monitoring allows clinicians to assimilate patient data and identify those patients showing early signs and symptoms of impending OIUAS and OIRD that require immediate actions (e.g., more frequent monitoring, reduction in opioid dose, discontinuation of an opioid, and/or activation of a rapid response team). It is important for organizations to provide and require completion of education of clinicians in how to effectively assess and use trend monitoring analysis of patient data to promote patient safety. Education regarding the proper implementation, use and interpretation of equipment, use of demonstrated data, and interventions to promote patient safety is also essential. Alarm events from electronic monitoring devices also signal potential or actual changes in respiratory status that may necessitate prompt interventions to prevent a decline in respiratory status. Additionally, safe patient care includes the assessment for adverse effects of monitoring procedures. According to a new TJC alert, periodic physical, psychological, and psychosocial assessment for pressure injury from continuous monitoring devices is recommended (The Joint Commission, 2018b). Clinicians need to be educated on how to use assessment tools, interpret patient data, and appropriately intervene to provide optimal safe patient care within the organization where they are employed.

Timing of assessments for opioid-induced advancing sedation and respiratory depression should be standardized using hospital policies and procedures. Clinical staff must receive appropriate education, and EHR systems could include alerts and reminders reflecting timing. Clinicians must be supported in using their critical thinking skills when evaluating patients for safe and effective pain management strategies. Policies and procedures should

### Table 7

<table>
<thead>
<tr>
<th>Assessment Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>End Tidal Carbon Dioxide (ETCO2)</td>
</tr>
<tr>
<td>• Capnography is a device that measures exhaled end tidal CO2 levels via a cannula positioned under the nasal nares and a scoop that sits over the upper portion of the mouth.</td>
</tr>
<tr>
<td>• Capnography is applied as a continuous monitoring strategy as opposed to intermittent.</td>
</tr>
<tr>
<td>• Evidence for the effectiveness of continuous electronic monitoring using capnography indicates improved patient safety outcomes when using opioids (Carlisle, 2015; Eversole, Shank, Scarfo, &amp; Thompson, 2008; Overdyk et al., 2007). There is a lack of evidence that capnography is more effective than continuous pulse oximetry in the detection of OIRD (Wall, Magee, Campbell, &amp; Zed, 2017).</td>
</tr>
<tr>
<td>• Normal values of end tidal CO2 range 35 to 45 mm Hg.</td>
</tr>
<tr>
<td>• Really low values represent lack of breath/hypoventilation.</td>
</tr>
<tr>
<td>• Values &gt;50 represent carbon dioxide retention/respiratory insufficiency.</td>
</tr>
<tr>
<td>• Monitoring with capnography has been found to significantly reduce the incidence of OIUAS and OIRD with patient-controlled analgesia (PCA) by 79% as measured by decreased rapid response team (p &lt; .001) and rate of transfers to a higher level of care (Stites et al., 2017).</td>
</tr>
<tr>
<td>• Barriers to the use of capnography on general care units are lack of nursing knowledge of the device and interpretation of ETCO2 levels, cost, availability of equipment, and patient adherence (Carlisle, 2015; Langhan, Kurtz, Schaeffer, Asnes, &amp; Riera, 2014).</td>
</tr>
</tbody>
</table>

**OIROD** — opioid-induced respiratory depression; **OIUAS** — opioid-induced unintended advancing sedation.

### Table 8

<table>
<thead>
<tr>
<th>Assessment Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minute Ventilation</td>
</tr>
<tr>
<td>• Minute ventilation (MV) is calculated using a measure of tidal volume (TV) and respiratory rate (RR).</td>
</tr>
<tr>
<td>• The respiratory volume monitor uses biopotential to provide real-time measurement of MV via electrodes placed at the sternal and midaxillary placements (Holley et al., 2016).</td>
</tr>
<tr>
<td>• The display shows the MV, TV, and RR as well as a comparison with the patient’s normal readings.</td>
</tr>
<tr>
<td>• Traditionally, the alarm is set at ≤ 40% of predicted/normal MV.</td>
</tr>
<tr>
<td>• Possible issues with the measurement of MV include lack of detection of breath in obese patients, electrodes not adhering and delivering inconsistent and accurate readings as a result of chest wall hair and artifact from patient movement.</td>
</tr>
<tr>
<td>• To date, few companies manufacture RVM devices for use on general care units. This technology is relatively new but has been well tested and is being used in PACUs, during procedural sedation in ambulatory centers, and more recently in the pediatric population.</td>
</tr>
</tbody>
</table>

RVM — respiratory volume monitoring; PACU — postanesthesia care unit.
support the autonomy of nurses to initiate appropriate monitoring strategies directed at improving patient safety especially in the first 24 hours of postoperative care or after initiation of parenteral opioids. Clinicians need to be educated regarding safety concerns, as well as the policies and procedures for assessment and monitoring of patients who receive intravenous and neuraxial opioids at the organization where they are employed.

Clinicians need ongoing education to ensure full understanding of the importance of pain, sedation, and respiratory assessments; which tools and assessment criteria are to be used; and how to most effectively intervene when sedation progresses and/or respiratory function is compromised (e.g., rapid response, transfer to higher level of care, code blue) at the organization where they are employed. Some facilities that have instituted continuous monitoring have published their procedures and outcomes to aid other facilities in the implementation of monitoring practices (Carlisle, 2015; Stites et al., 2017; Supe et al., 2017; van Loon, van Zaane, Bosch, Kalkman, & Peelen, 2015).

**Recommendation 11**

- The panel recommends the judicious use of naloxone based on patient evidence of life-threatening adverse events (strong recommendation, moderate level evidence).

**Rationale.** Naloxone rescue should be initiated at a dose less than or equal to 0.05 mg intravenous or intramuscular over 1 minute and repeated frequently based on institutional protocol and patient response until sedation and respiratory issues resolve (Connors & Nelson, 2016). The panel recommends that when naloxone reversal is required, clinicians consider the duration of action of naloxone and the duration of action of the opioid and implement frequent monitoring of the patient for any ongoing signs of OIUAS and OIRD.

**Implementation.** All clinicians need to be educated regarding indications for naloxone, pharmacology of naloxone, appropriate administration, and monitoring of patients after administration. Nurses should be involved in tracking the frequency of and reasons for naloxone administration to better understand factors contributing to its use.

**Education**

**Recommendation 12**

- The panel recommends clinician education on evidence-based and best practices for (1) determining patient risks for opioid-induced unintended advancing sedation and respiratory depression; (2) best practices on assessing level of sedation and respiratory status; (3) use of trend monitoring as opposed to threshold monitoring when evaluating indicators for respiratory status; (4) appropriate use of positive airway pressure therapy; (5) early implementation of appropriate interventions when advancing sedation and respiratory depression are imminent; and (6) appropriately educating patients and family members who want to know how to participate in safety efforts (strong recommendation, weak level evidence).

**Rationale.** Education of clinicians is paramount to promoting safe patient care and empowering clinicians to make independent and interdependent clinical decisions in designing sedation and respiratory monitoring plans of care and interpreting and responding to monitoring data (Youngcharoen, Vincent, & Park, 2017). The ASPMN expert panel strongly endorses interprofessional education, team-based care, and hospital- and system-wide structures and processes to support safe administration of opioid analgesics. Patients and family members who want to participate in patient safety efforts can offer important assistance with those efforts (Duhn & Medves, 2018; Schwappach, 2010; See, Chan, Huggan, Tay, & Liaw, 2014).

**Implementation Strategies and Surveillance.** Several publications offer evidence-based and best practices in redesigning processes and outcome measures to promote safer environments of care (Durham et al., 2017; Jungquist, Pasero, et al., 2014; Jungquist et al., 2017).

**Policies and Procedures**

**Recommendation 13**

- The panel recommends that hospital leadership support the development of practice and administrative policies and procedures that outline the implementation of strategies focusing on (1) clinician, patient, and family awareness of and strategies to avoid the problem; (2) education of clinicians, patient, and family on risk assessment and adaptation of individualized monitoring procedures and policies; and (3) proper training on the use of electronic monitoring systems with potential use of risk alerts within electronic health record systems (strong recommendation, moderate level evidence).

- The panel recommends the development of evidence-based policies and procedures that support education of clinicians, patients, and family members about the patient’s use of positive airway pressure devices to treat obstructive sleep apnea and obesity hypoventilation syndrome during hospitalization (strong recommendation, weak level evidence).

**Rationale.** As per recommendations from the IHI and TJC, health care facilities are responsible to ensure safe patient care. Appropriate policies and procedures that promote safe care are mandatory for safe care (Chahramanian, Rezaei, Abdullahzadeh, Sheikhalipour, & Dianat, 2017; Youngcharoen et al., 2017). The addition of communication alerts within the EHR may be a useful tool to remind clinicians of risk factors. Surveillance of adverse events continues to be recommended, with root cause analysis performed on events resulting in patient harm. Quality assurance reviews and surveillance of rapid response calls and naloxone administration are helpful to discover trends in near-miss events (Jungquist, Pasero, et al., 2014). Clinical guidelines for the perioperative management of the patient with sleep-disordered breathing are available to support implementation of positive airway pressure therapy. Policies and procedure development should be followed with clinician education.

**Implementation.** It is imperative that all clinicians are educated about the policies and procedures regarding pain, opioids, and related assessments and monitoring. Competency-based education should be considered for monitoring technology to ensure proficiency and the appropriate level of technical skills for troubleshooting device issues and interpreting monitoring data. Reeducation of all clinicians is necessary after any updates or modifications of the policies and procedures.

**Conclusions**

ASPMN charged a panel of experts with revising the 2011 published guidelines for monitoring hospitalized patients for opioid-
induced unintended advancing sedation and respiratory depression. The panel reviewed the most recent (past 10 years) evidence and developed revised recommendations that are more specific regarding assessment of risk and monitoring procedures. Many of the 2011 published recommendations remain current and should continue to be followed. Key revisions include (1) multiparameter nursing assessment, including respiratory rate and quality, pulse oximetry, and level of sedation before opioid and again at peak effect; (2) clinician reassessments comparing present patient data to previous data to assess change over time (trend monitoring); (3) the consideration for continuous electronic respiratory monitoring during the first 24 hours after surgery or initiation of parental opioid medications; and (4) patient-centric selection of type of electronic monitoring device.

Lastly, it is the responsibility of the entire health care team to ensure safe prescribing and use of opioids across all transitions of care. Although these ASPMN guidelines are applicable to safe and effective management of pain in hospitalized adults, all health care professionals should be mindful of the same, especially for ambulatory postoperative patients at discharge. The panel urges clinical nurses and advanced practice registered nurses, especially prescribers of opioids, to consult recent opioid prescribing guidelines for common surgical procedures (Chou et al., 2016; Overton et al., 2018).

Appendix: The guidelines authors wish to thank the external reviewers for their time and expertise.

List of External Reviewers

1. Michele Yurgil, M.S.N., R.N., A.C.N.S.-B.C., A.P.N., Clinical Nurse Specialist, Pain Management, Aurora St. Luke’s Medical Center, 2901 W. Kinnickinnic River Parkway, MBA 1, Suite 405, Advanced Practice Nursing, Milwaukee, WI 53215 USA. Michele.Yurgil@aurora.org
2. Stephanie Uses, Pharm.D., M.J., J.D., ECRI Institute, 5200 Butler Pike Plymouth Meeting, PA 19462-1928 USA. sus@s. ecri.org
4. Elizabeth Card, M.S.N., A.P.N., F.N.P.-B.C., C.P.A.N., C.C.R.P., ASPAN Director of Research, American Society of Peri-Anesthesia Nurses—(ASPN), 90 Frontage Road, Cherry Hill, NJ 08034 USA. ecard@aspan.org
5. Sue Jervik B.S.N., R.N.-B.C., Pain Management Educator, PIH Health Hospital, Whittier, CA, USA. Sue.Jervik@pihealth.org
6. Deb Gordon, R.N., D.N.P., F.A.A.N., Anesthesiology & Pain Medicine, Co-Director Harborview Integrated Pain Care Program, University of Washington Box 359733 Office 6EC-05, 325 Ninth Ave, Seattle WA 98104 USA. Debrag3@u.washington.edu
7. Jeffrey Fedin, Pharm.D., D.A.I.P.M., F.C.C.P., F.A.S.H.P., F.F.S.M.B., Chief Executive Officer & Chief Medical Officer, Remitage, LLC, Owner & Managing Editor, PainDr.com & Pain Blog, Adjunct Associate Professor, Western New England University College of Pharmacy, Adjunct Associate Professor of Pharmacy Practice & Pain Management, Albany College of Pharmacy & Health Sciences, Section Co-Editor, Pain Medicine (Opioids, Substance Abuse and Addictions Section). http://www.paindr.com | http://www.noverdoseapp.com
8. Colleen J. Dunwoody, M.S., R.N., Research Associate, University of Pittsburgh School of Nursing, 140 LaValle Drive, Apt 512, Monroeville, PA 15146 USA
9. Paul Arnstein, Ph.D., R.N., F.A.A.N., 55 Fruit Street #FND 345, Boston, MA 02114 USA. PMARNSTEIN@mhg.harvard.edu
10. Suzanne Karan, M.D., Anesthesiology, University of Rochester Medical Center, Rochester, NY 14642 USA. Suzanne_Karan@URMC.Rochester.edu
11. Frank J. Overdyk, M.S.E.E., M.D., Professor of Anesthesiology, Medical University of South Carolina, Charleston, SC 29403 USA. foverdyk@gmail.com

References


